Contineum Therapeutics, Inc. (CTNM) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
Stifel Reiterates Buy Rating on Contineum Therapeutics (CTNM)
August 15, 2024 7:46 AM EDTStifel analyst Paul Matteis reiterated a Buy rating and $29.00 price target on Contineum Therapeutics (NASDAQ: CTNM).
The analyst comments "We remain Buy rated on CTNM following their 2Q24 earnings release. Our thesis on CTNM primarily centers around their LPA1 receptor antagonist... More
